JP2015518819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518819A5 JP2015518819A5 JP2015511675A JP2015511675A JP2015518819A5 JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5 JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5
- Authority
- JP
- Japan
- Prior art keywords
- viral protein
- protein complex
- animal
- viral
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| US61/644,830 | 2012-05-09 | ||
| PCT/US2013/040228 WO2013169961A1 (en) | 2012-05-09 | 2013-05-09 | Conformationally specific viral immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Division JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015518819A JP2015518819A (ja) | 2015-07-06 |
| JP2015518819A5 true JP2015518819A5 (cg-RX-API-DMAC10.html) | 2016-06-30 |
Family
ID=49548782
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20130302366A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2846828B1 (cg-RX-API-DMAC10.html) |
| JP (4) | JP2015518819A (cg-RX-API-DMAC10.html) |
| AU (5) | AU2013259548A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2873048C (cg-RX-API-DMAC10.html) |
| IN (1) | IN2014DN09445A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013169961A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| JP6704849B2 (ja) | 2013-08-03 | 2020-06-03 | アバター・メディカル・エルエルシー | インフルエンザヘマグルチニンタンパク質およびその方法 |
| CN111405907B (zh) | 2017-08-07 | 2024-10-01 | 考尔德生物科技有限公司 | 构象稳定的rsv预融合f蛋白 |
| WO2019178521A1 (en) | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| JP2023526274A (ja) * | 2020-05-12 | 2023-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｓａｒｓ－ｃｏｖ２中和単一ドメイン抗体構築物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| ATE454901T1 (de) | 1999-10-13 | 2010-01-15 | Novartis Vaccines & Diagnostic | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
| ES2367475T3 (es) * | 1999-10-15 | 2011-11-03 | Avatar Medical, L.L.C. | Proteínas estabilizadas. |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| AU2002360673A1 (en) | 2001-12-17 | 2003-06-30 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Gp41 inhibitor |
| WO2004069863A2 (en) | 2003-02-04 | 2004-08-19 | New York University | Constrained hiv v3 loop peptides as immunogens and receptor antagonists |
| ATE532793T1 (de) * | 2003-07-03 | 2011-11-15 | Avatar Biotechnologies Inc | Verfahren zur herstellung von molekülen mit verminderter immunogenität |
| EP1755667B1 (en) * | 2004-06-01 | 2013-07-17 | Merck Sharp & Dohme Corp. | Stable peptide mimetic of hiv gp41 fusion intermediate |
| EP2040747A4 (en) * | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE |
| HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2009048631A1 (en) * | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF |
| SMT202000101T1 (it) * | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| WO2011066221A1 (en) | 2009-11-24 | 2011-06-03 | International Aids Vaccine Initiative | Immunogen prioritization for vaccine design |
| EP2572196A4 (en) | 2010-05-18 | 2014-04-23 | Christopher P Marshall | ASSAY TO IDENTIFY ANTIGENES FOR THE ACTIVATION OF B-CELL RECEPTORS WITH NEUTRALIZING ANTIBODIES |
| WO2013063366A2 (en) * | 2011-10-27 | 2013-05-02 | Stc.Unm | Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries |
| CN104471064B (zh) | 2012-01-20 | 2018-11-02 | 中华人民共和国香港特别行政区政府 | 副粘病毒及其用途 |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/en not_active Not-in-force
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en not_active Ceased
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/en active Pending
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en not_active Ceased
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja not_active Expired - Fee Related
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2023
- 2023-08-25 US US18/455,787 patent/US20240238369A1/en not_active Abandoned
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
-
2025
- 2025-09-11 US US19/326,552 patent/US20260158104A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Skarlupka et al. | Universal influenza virus neuraminidase vaccine elicits protective immune responses against human seasonal and pre-pandemic strains | |
| Lanzavecchia et al. | Antibody-guided vaccine design: identification of protective epitopes | |
| Margine et al. | Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses | |
| Khurana et al. | Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets | |
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| JP2020039347A (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Fontana et al. | Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| JP2020125323A5 (cg-RX-API-DMAC10.html) | ||
| Tan et al. | Recent advancements in combination subunit vaccine development | |
| JP2014530010A5 (cg-RX-API-DMAC10.html) | ||
| Rosendahl Huber et al. | Synthetic long peptide influenza vaccine containing conserved T and B cell epitopes reduces viral load in lungs of mice and ferrets | |
| JP2017035093A5 (cg-RX-API-DMAC10.html) | ||
| Wu et al. | A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus | |
| JP2014237714A5 (cg-RX-API-DMAC10.html) | ||
| JP2015524422A5 (cg-RX-API-DMAC10.html) | ||
| HRP20241498T1 (hr) | Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3) | |
| Xu et al. | Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines | |
| JP2012501959A5 (cg-RX-API-DMAC10.html) | ||
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| Verma et al. | Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies | |
| MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b | |
| Castro et al. | Computational design of vaccine immunogens | |
| Benen et al. | Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein |